^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hodgkin Lymphoma

    Related cancers:
    2d
    Pulmonary Sarcoidosis Associated With Pleural Effusion: A Case Report. (PubMed, Respirol Case Rep)
    The patient achieved complete clinical, biochemical and radiological remission following systemic corticosteroid therapy. This case highlights the importance of a rigorous differential diagnostic approach and careful clinicoradiological-histopathological correlation in rare presentations of sarcoidosis.
    Journal • Pleural effusion
    |
    IL2 (Interleukin 2)
    2d
    Utility of ultrasensitive, US Food and Drug Administration-approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas. (PubMed, Am J Clin Pathol)
    Although morphology and immunohistochemistry are usually sufficient to separate CHL from NLPHL, determining light chain restriction by K/L dual ISH could provide a valuable adjunct in challenging cases, potentially improving diagnostic accuracy and patient outcomes.
    FDA event • Journal
    |
    VENTANA HER2 Dual ISH DNA Probe Cocktail
    2d
    Novel therapeutic targets at the crossroad between epigenetics and signal transduction pathways in B-cell lymphomas. (PubMed, Clin Exp Med)
    This review explores the function of newly recognized kinases in lymphoma pathogenesis, such as CK1, CK2 and others, highlighting their interaction with epigenetic regulation. The therapeutic potential of targeting simultaneously signaling and epigenetic pathways is proposed as a potential innovative strategy in the treatment of lymphomas.
    Review • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    5d
    NAHL: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, University of Utah | Trial completion date: Apr 2028 --> Nov 2028 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Niktimvo (axatilimab-csfr)
    5d
    AHOD03P1: Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease (clinicaltrials.gov)
    P2, N=188, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Dec 2030 --> Mar 2026
    Trial completion • Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine
    6d
    Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, St. Jude Children's Research Hospital | Initiation date: Apr 2026 --> Aug 2026
    Trial initiation date
    6d
    Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Florida | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • CBL mutation
    6d
    Genetic risk and immune dysregulation of classic Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a multicentric study. (PubMed, medRxiv)
    Classic Hodgkin lymphoma-type Richter transformation arises from convergent Hodgkin-like immune evasion on a genetically primed CLL/SLL background. Through integrated genomic and tumor microenvironment analyses in a large multicenter cohort, we establish this as a biologically coherent entity and provide rationale for PD-L1/PD-L2-directed therapeutic strategies.
    Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • PD-L2 (Programmed Cell Death 1 Ligand 2) • BIRC3 (Baculoviral IAP repeat containing 3) • XPO1 (Exportin 1)
    |
    PD-L1 expression
    6d
    Immune checkpoint therapy in pediatric and adolescent lymphomas. (PubMed, Haematologica)
    In PMBCL, the Children's Oncology Group (COG) and the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) recently completed a randomized phase III trial of nivolumab in combination with chemo-immunotherapy in children and adults with newly diagnosed PMBCL...In ALCL and ANKL, ongoing clinical trials are evaluating the efficacy of ICT. Given the transformational role of ICT for pediatric Hodgkin lymphoma, there is significant promise for the use of ICT in multiple subtypes of pediatric non-Hodgkin lymphoma with increased expression of PD-L1.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)
    6d
    Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=118, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    7d
    NCI-2021-13436: CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Onureg (azacitidine oral)